Silence Therapeutics share price logo

Silence Therapeutics

NASDAQ: SLN

Small Cap

$10.64

-0.07

(-0.65%)

as on

Silence Therapeutics Stock Performance

as on October 3, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $10.38
    $10.73
    downward going graph

    2.44%

    Downside

    0.85%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $4.19
    $17.58
    downward going graph

    60.62%

    Downside

    65.19%

    Upside

    downward going graph

Silence Therapeutics share price movements today

Previous Close
$10.71
Open
$10.65
Volume
917.8K
Market Cap
$665.7M
Day's Low - High
$10.38 - $10.73
52 Week Low - High
$4.19 - $17.58

Silence Therapeutics Historical Returns

1 Month Return
-28.06 %
3 Month Return
+ 2.41 %
1 Year Return
+ 112.8 %
3 Year Return
+ 17.44 %
5 Year Return
-48.37 %

Silence Therapeutics Stock Fundamentals & Key Indicators

Check Silence Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$665.7M

EPS (TTM)

-3.81

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.8

Industry PE ratio

-6.16

PEG Ratio

-0.20

EBITDA

-60.3M

Revenue (TTM)

614.3K

Profit Margin

51.00%

Return On Equity TTM

-106.94%

Silence Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Silence Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$665.7M-48.37%-2.8051.00%0.00%
StrongBuy$44.1B609.62%-23.340.00%0.00%
Neutral$75.4B-44.29%-24.08-12.57%0.00%
StrongBuy$132.5B180.98%30.1986.04%0.00%
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Silence Therapeutics Stock including INR - Dollar returns

The Silence Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Silence Therapeutics investment value today

Current value as on today

₹2,30,942

Returns

₹1,30,942

(+130.94%)

Returns from Silence Therapeutics Stock

₹1,12,800 (+112.8%)

Dollar Impact

₹18,142 (+18.14%)

Analyst Recommendation on Silence Therapeutics Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Silence Therapeutics. Average target price of $33

Silence Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Silence Therapeutics.

What analysts predicted

67.76%UPSIDE

Target Price

$33

Current Price

$10.64

Analyzed by

2 Analysts

High

$75

Target

$33.00

Low

$75

Silence Therapeutics target price $33, a slight upside of 67.76% compared to current price of $10.64. According to 2 analysts rating.

Indian Investors' Interest in Silence Therapeutics Stock

Search interest for Silence Therapeutics Stock has decreased by -83% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-83% versus previous 30 day period

Silence Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
15
0
1
24
0
0
0
0
0
-
Gross Profit
12
-2
-1
22
0
0
0
0
0
0
Operating Income
-5
-18
-22
-3
-36
-32
-26
-12
-15
-13
EBITDA
-2
-17
-21
7
-36
-30
-20
-11
-14
-13
Interest Expense
0
0
8
-11
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-2
-17
-30
23
-36
-37
-20
-11
-14
-12
Income Tax Expense
0
-1
-3
9
-
0
0
-
-
0
Net Income
-2
-15
-27
14
-36
-37
-20
-11
-14
-12
Net Profit Margin
82.16%
-341.14%
-142.91%
93.40%
61.97%
62.05%
59.75%
64.71%
72.27%
0.00%

Silence Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
0
5
12
17
25
43
0
Gross Profit
-7
-9
0
1
4
6
15
31
0
Operating Income
-14
-20
-22
-35
-45
-49
-49
-63
-89
EBITDA
-3
-20
-22
-35
-45
-39
-49
-48
-88
Interest Expense
0
-
0
0
0
0
0
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-3
-20
-22
-36
-45
-40
-50
-44
-88
Income Tax Expense
-2
-2
-3
-3
-6
0
-7
0
0
Net Income
-1
-18
-19
-32
-39
-41
-43
-45
-88
Net Profit Margin
-49543.75%
0.00%
100.00%
31.34%
39.94%
37.83%
59.34%
72.70%
61.54%

Silence Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-2
-19
-41
22
-22
-27
-20
-82
-14
-12
Operating Cash Flow
-9
-5
-19
-24
-12
-21
-10
-17
-15
1
Investing Cash Flow
-49
0
-28
54
-44
-1
51
-53
10
64
Financing Cash Flow
133
1
5
-6
0
0
0
0
-
0
Change in Cash
73
-4
-47
34
-56
-23
40
-70
-5
66

Silence Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-3
-20
-22
-36
-61
-50
-50
-28
-88
Operating Cash Flow
-9
-16
1
-10
9
-57
-39
-54
-62
Investing Cash Flow
13
-4
-15
9
11
-20
16
-17
-47
Financing Cash Flow
0
0
5
15
41
52
25
113
0
Change in Cash
3
-21
-7
13
62
-33
0
41
-110

Global Institutional Holdings in Silence Therapeutics

Check out the Institutions with significant holdings in Silence Therapeutics.

Funds
Holdings
iShares
0.60%
Fidelity Concord Street Trust
0.05%
State Street
0.04%
Steward Funds Inc
0.02%
ActivePassive
0.02%

Insights on Silence Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -14.93M → -12.29M (in $), with an average increase of 21.5% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 34.0K → 421.29K (in $), with an average increase of 91.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 84.3% return, outperforming this stock by 66.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 454.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, SLN stock has moved down by -28.1%

About Silence Therapeutics

Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
OrganisationSilence Therapeutics
Headquarters72 Hammersmith Road, London, GL, W6 7AP, GB
IndustryBiotechnology
CEOIain Gladstone Ross

Key Management of Silence Therapeutics

Name

Title

Dr. Marie Wikstrom Lindholm Ph.D.

Chief Scientific Officer

Ms. Gem Gokmen Hopkins

Head of IR & Corporate Communications

Mr. Jaimin B. Shah

SVP & General Counsel

Mr. J.P. Gabriel

Chief Technical Operations Officer

Mr. Curtis Rambaran M.D.

Chief Medical Officer

Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D

Interim CEO & Chairman of the Board

Ms. Rhonda L. Hellums

Executive VP, CFO, Secretary & Executive Director

Dr. Steven J. Romano M.D.

Executive VP and Chief Research & Development Officer

FAQs

What is Silence Therapeutics share price today?

Silence Therapeutics share price today is $10.64 as on at the close of the market. Silence Therapeutics share today touched a day high of $10.73 and a low of $10.38.

What is the 52 week high and 52 week low for Silence Therapeutics share?

Silence Therapeutics share touched a 52 week high of $17.58 on and a 52 week low of $4.19 on . Silence Therapeutics stock price today i.e. is closed at $10.64,which is 39.46% down from its 52 week high and 153.94% up from its 52 week low.

What is Silence Therapeutics's market capitalisation today?

Silence Therapeutics market capitalisation is $0.00T as on .

How to invest in Silence Therapeutics Stock (SLN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Silence Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Silence Therapeutics Stock (SLN) from India?

Indian investors can start investing in Silence Therapeutics (SLN) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Silence Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Silence Therapeutics share’s latest price of $10.64 as on October 3, 2026 at 8:46 am IST, you will get 0.9398 shares of Silence Therapeutics. Learn more about fractional shares .

What are the returns that Silence Therapeutics has given to Indian investors in the last 5 years?

Silence Therapeutics stock has given -48.37% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?